Non-Retatrutide Research Peptides: Dubai Catalog and COA Map
A verification-first guide to Remy Peptides' non-retatrutide research line: GLOW, tirzepatide, SS-31, AOD-9604, PT-141, CJC-1295 + Ipamorelin, BPC-157, TB-500, BPC-157 + TB-500, GHK-Cu, KPV, MOTS-C, Tesamorelin, and HCG. The focus is catalog identity, line-standard HPLC purity, stock status, and where the published evidence stops.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
Remy Peptides' non-retatrutide line is best read as a catalog of research-use compounds, not as a clinical recommendation set. As of June 14, 2026, the live catalog lists 13 non-retatrutide products as orderable and two as currently unavailable. The non-retatrutide line is supplied to a >99% HPLC line standard, but Remy Peptides does not present public batch-specific Janoshik COAs for each non-reta product yet. This page maps the current product pages, research guides, evidence anchors, and RUO boundaries in one place.
What Counts as Non-Retatrutide on Remy Peptides?
For this article, non-retatrutide means every Remy Peptides catalog item outside the retatrutide pen and vial line. That includes single-compound research vials such as BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg, SS-31, MOTS-C 10mg, AOD-9604 10mg, KPV 10mg, PT-141 10mg, and Tesamorelin 10mg, plus blends such as GLOW 70mg Pen, CJC-1295 + Ipamorelin, and BPC-157 + TB-500. Tirzepatide 40mg Vial is also included because it is a non-retatrutide research vial in the Remy catalog.
The article is designed as a parent map. Use it to understand the category, then use the linked product page for live stock and format data, and the linked research guide for compound-specific evidence boundaries.
Live Catalog Map: Stock, Format, and Route
The table below mirrors live catalog facts checked on June 14, 2026. Product pages remain the source of truth because orderability, pack tiers, and restock state can change.
| Product | Research format | Status | Live route | Support guide |
|---|---|---|---|---|
| GLOW 70mg Pen | 50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500 prefilled pen | In stock | Product page | GLOW vs individual vials |
| Tirzepatide 40mg Vial | 40mg lyophilized dual GIP/GLP-1 receptor agonist vial | In stock | Product page | Tirzepatide UAE vial guide |
| SS-31 10mg and 50mg | Mitochondrial-targeted tetrapeptide vial formats | In stock | Product page | SS-31 Dubai guide |
| AOD-9604 10mg | hGH fragment-derived peptide vial | In stock | Product page | AOD-9604 Dubai guide |
| PT-141 10mg | Melanocortin analog peptide vial | In stock | Product page | PT-141 Dubai guide |
| CJC-1295 + Ipamorelin | 5mg + 5mg combined lyophilized research blend | In stock | Product page | CJC + Ipamorelin guide |
| BPC-157 10mg | Synthetic pentadecapeptide vial | In stock | Product page | BPC-157 Dubai guide |
| TB-500 10mg | Synthetic thymosin beta-4 fragment vial | In stock | Product page | TB-500 Dubai guide |
| BPC-157 + TB-500 | 5mg + 5mg combined lyophilized research blend | In stock | Product page | Blend Dubai guide |
| GHK-Cu 50mg | Copper-binding tripeptide vial | In stock | Product page | GHK-Cu Dubai guide |
| KPV 10mg | Lys-Pro-Val tripeptide vial | In stock | Product page | KPV Dubai guide |
| MOTS-C 10mg | Mitochondrial-derived 16-residue peptide vial | In stock | Product page | MOTS-C Dubai guide |
| Tesamorelin 10mg | GHRH analog peptide vial | Currently unavailable | Product page | Tesamorelin guide |
| HCG 5000iu | Chorionic gonadotropin reference-format vial | Currently unavailable | Product page | HCG Dubai guide |
How to Read the Purity Claim
The key distinction is line-standard purity versus public batch-specific COA proof. Retatrutide pages on Remy Peptides include published batch-specific Janoshik records for specific products. The non-retatrutide research line is handled differently: the catalog states these products are supplied to a >99% HPLC line standard, while also stating that no public batch-specific Janoshik COA is published for each non-reta product yet.
That distinction matters. It lets Remy Peptides support catalog confidence without over-claiming a public lot file that is not posted. For a current source check, use the product page, the COA library, and official contact verification.
| Proof layer | What Remy can say | What Remy should not imply |
|---|---|---|
| Line-standard HPLC | Non-reta research peptides are supplied to a >99% HPLC line standard. | That every non-reta product has a public batch-specific Janoshik file posted today. |
| Published batch-specific COA | Use where a named public report exists, such as published retatrutide batch records. | Do not transfer retatrutide COA proof onto non-reta products. |
| Product page facts | Format, stock label, route, pack tier, and current orderability. | Stock and pricing are live — confirm on the product page, not from this article. |
Evidence Map and Translation Limits
The source ledger below anchors compound identity and research context. It does not convert any catalog item into a human-use or veterinary-use product.
| Compound or group | What the literature anchors | Research-use boundary |
|---|---|---|
| BPC-157 | Recent reviews describe BPC-157 as a synthetic Body Protection Compound peptide with a literature base weighted toward preclinical and review-level findings.[1] | Identity and evidence context only; no outcome claims. |
| TB-500 / thymosin beta-4 fragment | Thymosin beta-4 and actin-binding fragments are studied around actin dynamics and tissue-repair models.[2] | Useful for mechanism framing, not a healing claim. |
| GHK-Cu | GHK-Cu is discussed as a copper-binding tripeptide with gene-expression and tissue-remodeling research context.[3] | Do not translate topical/cellular literature into personal-use instructions. |
| MOTS-C | MOTS-C is a mitochondrial-derived peptide encoded in the mitochondrial genome and studied through metabolic-signaling pathways.[4] | Research signaling context only; no metabolic outcome promise. |
| SS-31 / elamipretide | SS-31 is a mitochondria-targeted tetrapeptide studied for interactions with lipid bilayers and mitochondrial surface electrostatics.[5] | Mechanism language should stay mitochondrial-research framed. |
| AOD-9604 | AOD-9604 is identified in analytical literature as an hGH C-terminal fragment-derived peptide, with detection and in-vitro metabolism work published.[6] | Use identity and analytical context; avoid weight-management claims. |
| CJC-1295 + Ipamorelin | CJC-1295 is a long-acting GHRH analog studied for GH/IGF-1 signaling, while ipamorelin is a selective growth hormone secretagogue in the GHRP family.[7][8] | GH-axis biology only; no body-composition, anti-aging, or protocol claims. |
| KPV | KPV is the Lys-Pro-Val C-terminal tripeptide sequence of alpha-MSH, studied in immune-signaling models.[9] | Use alpha-MSH fragment identity; avoid disease or inflammation promises. |
| PT-141 / bremelanotide | FDA label material identifies bremelanotide as a melanocortin receptor agonist and sets strict approved-use boundaries for the regulated drug product.[10] | A research vial is not an FDA-approved product or personal-use guide. |
| Tesamorelin | FDA label material identifies tesamorelin as a GHRH analog in the regulated EGRIFTA SV drug context.[11] | Regulated-drug label context does not authorize an RUO vial for use. |
| HCG | DailyMed label material describes chorionic gonadotropin as a polypeptide hormone with alpha and beta subunits in regulated drug products.[12] | Remy's HCG page is a reference-format research listing, not a clinical guide. |
| Tirzepatide | Peer-reviewed SURMOUNT-1 literature anchors tirzepatide as a dual GIP/GLP-1 receptor agonist in regulated obesity research.[13] | Use compound identity and published-study context only on RUO catalog surfaces. |
Where to Look Next
Each page in the non-retatrutide cluster has a clear role. Use this map to get oriented, then follow the path that matches what you need.
- Browsing the catalog: use All Products, GLOW 70mg Pen, and this non-reta map.
- Checking purity and proof: use Peptide COA & HPLC Purity Guide, COA Library, and Contact Verification.
- Reading the evidence: use the specific research guide for BPC-157, TB-500, SS-31, AOD-9604, MOTS-C, KPV, PT-141, CJC-1295 + Ipamorelin, Tesamorelin, HCG, Tirzepatide, or GLOW.
- Handling and storage: use Bacteriostatic Water Guide and Peptide Stability & Storage Guide.
What This Page Does Not Claim
This page supports discovery and verification for non-retatrutide research compounds. It does not claim that any product is intended for human administration, veterinary use, diagnosis, treatment, prevention, disease management, personal protocols, or outcomes. Evidence summaries are included to help researchers identify compounds and understand the limits of published literature, not to suggest use.
Where public label or study sources are cited, those sources are used only to anchor compound identity, mechanism class, or regulated-product boundaries. They do not change the Remy Peptides catalog status: For in-vitro laboratory research only. Not for human or veterinary use.
Our Research Standards
This guide draws on the live Remy Peptides product catalog checked on June 14, 2026, product-specific Remy research guides, PubMed-indexed studies, FDA label documents, DailyMed label material, and Remy editorial compliance standards. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
Non-Retatrutide Research FAQ
What is a non-retatrutide research peptide on Remy Peptides?
On Remy Peptides, non-retatrutide research peptides are the catalog items outside the retatrutide pen and vial line: GLOW, tirzepatide, SS-31, AOD-9604, PT-141, CJC-1295 + Ipamorelin, BPC-157, TB-500, BPC-157 + TB-500, GHK-Cu, KPV, MOTS-C, Tesamorelin, and HCG. Each listing remains for in-vitro laboratory research only.
Which non-retatrutide products are currently orderable?
The live catalog lists GLOW 70mg Pen, Tirzepatide 40mg Vial, SS-31 10mg and 50mg, AOD-9604 10mg, PT-141 10mg, CJC-1295 + Ipamorelin 5mg/5mg, BPC-157 10mg, TB-500 10mg, BPC-157 + TB-500 5mg/5mg, GHK-Cu 50mg, KPV 10mg, and MOTS-C 10mg as orderable. Tesamorelin 10mg and HCG 5000iu are currently marked unavailable, so their product pages should be used for restock alerts and current status.
Does line-standard HPLC purity mean a public batch-specific COA is posted?
No. The non-retatrutide research line is supplied to a greater-than-99% HPLC line standard, but no public batch-specific Janoshik COA is posted for each product at the time of this article. Remy Peptides separates that line-standard claim from retatrutide products that have published batch-specific COAs.
Is this article a human-use or veterinary-use guide?
No. This article is a research-use catalog map. It does not provide human-use, veterinary-use, diagnostic, treatment, disease-management, administration, or personal protocol guidance.
Which page should researchers use next?
Use the live product page for stock, format, price tier, and current orderability. Use this article as the parent map, then open the linked product-specific research guide for deeper compound identity, evidence boundaries, and sourcing checks.
Sources
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. PMID: 40789979↑
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003. PMID: 12581423↑
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. PMID: 29986520↑
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID: 25738459↑
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID: 32273339↑
- Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2014. PMID: 25208511↑
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683↑
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID: 9849822↑
- Dissection of the anti-inflammatory effect of the core and C-terminal tripeptide sequences of alpha-melanocyte-stimulating hormone. Journal of Pharmacology and Experimental Therapeutics. 2003. PMID: 12750433↑
- U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) prescribing information. Revised June 2019. accessdata.fda.gov↑
- U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) prescribing information. Revised February 2024. accessdata.fda.gov↑
- DailyMed. Chorionic Gonadotropin kit drug label information. dailymed.nlm.nih.gov↑
- Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. nejm.org↑
For current stock, format, and price tiers, use the live Remy Peptides product catalog. For wider supplier verification, continue to the peptide COA guide and official contact verification.